Regulatory Compliance

# Regulatory Compliance for Clinical Reports ## HIPAA (Health Insurance Portability and Accountability Act) ### Overview HIPAA Privacy Rule protects individually identifiable health information (Protected Health Information, PHI). All clinical reports must comply with HIPAA requirements for privacy and security. ### Protected Health Information (PHI) **Definition:** Individually identifiable health information held or transmitted by covered entities or business associates in any form or medium. **Covered Entities:** - Healthcare providers - Health plans - Healthcare clearinghouses **Business Associates:** - Third parties providing services involving PHI - Require Business Associate Agreement (BAA) ### 18 HIPAA Identifiers These identifiers must be removed for Safe Harbor de-identification: 1. **Names** 2. **Geographic subdivisions smaller than state** (except first 3 digits of ZIP if >20,000 people) 3. **Dates** (except year) - birth, admission, discharge, death 4. **Telephone numbers** 5. **Fax numbers** 6. **Email addresses** 7. **Social Security numbers** 8. **Medical record numbers** 9. **Health plan beneficiary numbers** 10. **Account numbers** 11. **Certificate/license numbers** 12. **Vehicle identifiers and serial numbers** 13. **Device identifiers and serial numbers** 14. **Web URLs** 15. **IP addresses** 16. **Biometric identifiers** (fingerprints, voiceprints) 17. **Full-face photographs and comparable images** 18. **Any other unique identifying characteristic or code** ### De-identification Methods #### Method 1: Safe Harbor Remove all 18 identifiers AND have no actual knowledge that remaining information could be used to identify the individual. **Implementation:** - Remove/redact all 18 identifiers - Ages over 89 must be aggregated to "90 or older" - Dates can keep year only - Geographic areas can include state only - Documentation that no identifying information remains #### Method 2: Expert Determination Statistical/scientific analysis demonstrating that risk of re-identification is very small. **Requirements:** - Performed by qualified statistician or expert - Documented analysis methods - Conclusion that re-identification risk is very small - Maintained documentation ### HIPAA Minimum Necessary Standard **Principle:** Use, disclose, and request only the minimum PHI necessary to accomplish purpose. **Exceptions:** - Treatment purposes (providers need full information) - Patient-authorized disclosures - Required by law **Implementation:** - Role-based access controls - Purpose-specific disclosures - Limited data sets when feasible ### Patient Authorization **When required:** - Uses/disclosures beyond treatment, payment, operations (TPO) - Marketing purposes - Sale of PHI - Psychotherapy notes - Research (unless waiver obtained) **Required elements of authorization:** - Specific description of PHI to be used/disclosed - Person(s) authorized to make disclosure - Person(s) to receive information - Purpose of disclosure - Expiration date or event - Patient signature and date - Right to revoke - Potential for re-disclosure by recipient ### HIPAA Security Rule (Electronic PHI) **Administrative Safeguards:** - Security management process - Workforce security - Information access management - Security awareness and training - Security incident procedures **Physical Safeguards:** - Facility access controls - Workstation use and security - Device and media controls **Technical Safeguards:** - Access control - Audit controls - Integrity controls - Transmission security ### Breach Notification Rule **Breach definition:** Unauthorized acquisition, access, use, or disclosure of PHI that compromises security or privacy. **Notification requirements:** - **Individual notification:** Without unreasonable delay, no later than 60 days - **Media notification:** If breach affects >500 residents of a state or jurisdiction - **HHS notification:** Within 60 days if >500 individuals; annually if minimal risk) 9. Who to contact for questions 10. Statement that participation is voluntary 11. Statement that refusal will involve no penalty or loss of benefits 12. Statement that subject may discontinue at any time **Additional elements (when appropriate):** - Unforeseeable risks to subject or embryo/fetus - Circumstances of study termination by investigator - Additional costs to subject - Consequences of withdrawal - New findings that may affect willingness to participate - Approximate number of subjects **Documentation:** - Written consent required (unless waived) - Copy provided to subject - Subject or legally authorized representative must sign - Person obtaining consent must sign - Date of consent **Vulnerable populations:** - Children: Parental permission + assent (if capable) - Prisoners: Additional protections - Pregnant women: Additional protections for fetus - Cognitively impaired: Legal representative consent ### 21 CFR Part 56 (IRB Standards) **IRB composition:** - At least 5 members - Varying backgrounds - At least one scientist - At least one non-scientist - At least one member not affiliated with institution - No member may participate in review of study in which member has conflicting interest **IRB review criteria:** - Risks minimized - Risks reasonable in relation to benefits - Selection of subjects equitable - Informed consent obtained and documented - Data monitoring when appropriate - Privacy and confidentiality protected - Additional safeguards for vulnerable populations **IRB review types:** - Full board review - Expedited review (certain categories of minimal risk) - Exempt (certain categories) **Continuing review:** - At least annually - More frequent if determined by IRB - Review of progress, new information, consent process **Documentation:** - Written procedures - Meeting minutes - Review determinations - Correspondence - Retention of records for 3 years ### 21 CFR Part 312 (IND Regulations) **IND requirements:** - Investigator's Brochure - Protocol(s) - Chemistry, manufacturing, and controls information - Pharmacology and toxicology information - Previous human experience - Additional information (if applicable) **IND amendments:** - Protocol amendments - Information amendments - Safety reports - Annual reports **Safety reporting:** - IND safety reports (7-day and 15-day) - Fatal or life-threatening unexpected: 7 days (preliminary), 15 days (complete) - Other serious unexpected: 15 days - Annual safety reports **General investigational plan:** - Rationale for drug or study - Indications to be studied - Approach to evaluating drug - Kinds of trials planned (Phase 1, 2, 3) - Estimated duration of study ## EU Clinical Trials Regulation (CTR) **EU CTR 536/2014** (replaced Clinical Trials Directive 2001/20/EC) **Key requirements:** - Single submission portal (CTIS - Clinical Trials Information System) - Single assessment by multiple member states - Transparency requirements (EudraCT database) - Public disclosure of clinical trial results - Layperson summary of results required **Timelines:** - Assessment: 60 days (Part I), additional time for Part II - Substantial modifications: 38 days - Safety reporting: Within specified timelines to EudraVigilance ## Good Documentation Practice (GDP) ### Principles **ALCOA-CCEA:** - **A**ttributable: Who performed action and when - **L**egible: Readable and permanent - **C**ontemporaneous: Recorded when performed - **O**riginal: First capture of information (or certified copy) - **A**ccurate: Correct and truthful Additional: - **C**omplete: All data captured - **C**onsistent: Chronological sequence, no discrepancies - **E**nduring: Durable throughout retention period - **A**vailable: Accessible for review when needed ### Data Integrity **MHRA (UK) data integrity guidance:** - Data governance (ownership, quality) - Risk assessment - Change management - Training - Regular audit **Common data integrity issues:** - Back-dating of records - Deletion or hiding of data - Repeat testing without documentation - Transcription errors - Missing metadata - Inadequate audit trails --- This reference provides comprehensive guidance for regulatory compliance in clinical reports and clinical trials, including HIPAA, FDA regulations, ICH-GCP, and EU requirements. Ensure all clinical documentation adheres to applicable regulations.